This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)

Reference No. 3414

Publication date:

Appraisal information

bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) 50 mg/200 mg/25 mg film-coated tablet

Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 10/10/2018
AWMSG meeting date: 14/11/2018
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1918
Ratification by Welsh Government: 03/12/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is recommended as an option for restricted use within NHS Wales. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is licensed for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is restricted for use to patients who are either unsuitable for or unable to tolerate dolutegravir/abacavir/lamivudine (Triumeq®). Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
AWMSG Secretariat Appraisal Report (ASAR)
Final Appraisal Recommendation (FAR)